Weekly Digest – February 2026 Weekly Digest – February 2026 14 February 2026: Hengrui Medicine’s HER2 ADC, Trastuzumab Ruikang, has been included in the Breakthrough Therapy List for a new indication Hengrui Medicine announced that its independently developed HER2-targeting antibody–drug […]
Weekly Digest – February 2026 Weekly Digest – February 2026 14 February 2026: Alphamab Oncology announces the first patient dosed in a phase 3 clinical study for colorectal cancer of biparatopic HER2-targeting ADC JSKN003 Alphamab Oncology announced that the first […]
Weekly Digest – February 2026 Weekly Digest – February 2026 17 February 2026: BostonGene announces strategic collaboration with Daiichi Sankyo to accelerate drug development through AI-driven multimodal analytics BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven multimodal […]
Weekly Digest – February 2026 Weekly Digest – February 2026 19 February 2026: Affibody signs Letter of Intent with SHINE Technologies for supply of Lutetium-177 Affibody announced that it has signed a Letter of Intent with SHINE Technologies to secure […]
Weekly Digest – February 2026 Weekly Digest – February 2026 06 February 2026: Kelun-Biotech announces fourth indication for Sacituzumab Tirumotecan (sac-TMT) approved by NMPA in HR+/HER2- breast cancer Sichuan Kelun-Biotech announced that China’s National Medical Products Administration has approved a […]
Weekly Digest – February 2026 Weekly Digest – February 2026 12 February 2026: DATROWAY Supplemental New Drug Application submitted in Japan for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy Daiichi Sankyo has submitted a […]
Weekly Digest – February 2026 Weekly Digest – February 2026 11 February 2026: First patient dosed for a Phase 1b/2 clinical trial of PD-L1 ADC HLX43 combination therapy in advanced colorectal cancer Shanghai Henlius Biotech announced that the first patient […]
Weekly Digest – February 2026 Weekly Digest – February 2026 12 February 2026: Innovent dosed first participant in Phase 3 clinical study of IBI354 (novel HER2 ADC) for first line treatment of HER2-positive breast cancer Innovent Biologics announced that the […]
Weekly Digest – February 2026 Weekly Digest – February 2026 11 February 2026: Niowave and Novartis enter global Actinium-225 supply agreement to advance next-generation cancer therapies Niowave announced a new long-term global supply agreement with Novartis to provide Actinium-225 (Ac-225), […]
Weekly Digest – February 2026 Weekly Digest – February 2026 10 February 2026: Chugai Pharmaceutical and Araris Biotech AG enter into license agreement for Araris’ linker-payload ADC technology, AraLinQ Chugai Pharmaceutical and Araris Biotech announced that Chugai has exercised its […]
